Ask AI
ProCE Banner Activity

Turning Down the Heat in HS: Translating Emerging Mechanistic Insights and Biologic Innovation Into Meaningful Patient Outcomes

Slideset

Understanding how to recognize hidradenitis suppurativa (HS) across diverse skin tones and phenotypes can shorten diagnostic delays and prevent irreversible tissue damage. Use these expert-curated slides to learn about emerging mechanistic insights in HS, best practices for disease staging, and the latest data on biologic therapies, including how to translate these insights into practical treatment pathways to bring individualized care and shared decision-making strategies to patients with HS.

Released: August 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with HS Foundation and Integrative Dermatology Symposium/LearnSkin.

 
ProCE Banner

Supporters

Supported by an educational grant from Incyte Corporation.

Incyte Corporation

Partners

HS Foundation

ProCE Banner

Integrative Dermatology Symposium/LearnSkin

ProCE Banner

Target Audience

This activity is intended for dermatologists, nurse practitioners, physician associates, and other HCPs who care for people living with hidradenitis suppurativa.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement structured diagnostic and staging frameworks to reduce time-to-diagnosis and mitigate irreversible tissue damage in patients with HS

  • Individualize advanced therapeutic strategies by integrating efficacy benchmarks, safety considerations, and patient-reported outcomes into shared decision-making discussions

  • Operationalize comprehensive, patient-centered care models that integrate dermatology, surgery, pain management, and behavioral health to address the full burden of HS

Financial Disclosures

Primary Author

Steve Daveluy, MD, FAAD: consultant/advisor/speaker: AbbVie, Incyte, Leo, Novartis, UCB; researcher: AbbVie, Incyte, Insmed, Leo, MoonLake, Novartis, Pfizer, Regeneron, Sanofi, Takeda, UCB.

Venessa Peña-Robichaux, MD: stock/advisor: Osquo.